Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 18, 2017

Primary Completion Date

March 25, 2020

Study Completion Date

March 25, 2020

Conditions
Metastatic Colorectal CancerMetastatic Pancreatic Cancer
Interventions
DRUG

Olaptesed pegol - Monotherapy

"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"

DRUG

Olaptesed pegol + Pembrolizumab - Combination Therapy

"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"

Trial Locations (1)

69120

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

TME Pharma AG

INDUSTRY

NCT03168139 - Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer | Biotech Hunter | Biotech Hunter